Skip to main content
30 Days of MarketBeat All Access for $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more.
Start Your Risk-Free Trial Here

CRDF Insider Trading (Cardiff Oncology)

Insider Ownership Percentage: 0.60%
Insider Buying (Last 12 Months): $142,743.70
Insider Selling (Last 12 Months): $0.00

Cardiff Oncology Insider Trading History Chart

Cardiff Oncology Share Price & Price History

$8.55
▲ +0.06 (0.71%)
As of 05/14/2021 01:00 AM ET
Days: 30 | 90 | 365
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
Download Your FREE Options Trading Strategy Guide today!
pixel

Cardiff Oncology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2021Rodney S MarkinDirectorBuy2,900$10.32$29,928.007,181View SEC Filing Icon  
3/23/2021Mark ErlanderCEOBuy965$10.34$9,978.1014,481View SEC Filing Icon  
3/23/2021Vicki KelemenCOOBuy960$10.31$9,897.606,053View SEC Filing Icon  
3/22/2021John P BrancaccioDirectorBuy3,000$10.95$32,850.0012,260View SEC Filing Icon  
3/18/2021Gary W PaceDirectorBuy3,000$10.55$31,650.00452,811View SEC Filing Icon  
3/4/2021Gary W PaceDirectorBuy1,500$9.27$13,905.00451,811View SEC Filing Icon  
9/16/2020Gary W PaceDirectorBuy2,550$5.70$14,535.00449,461View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Cardiff Oncology (NASDAQ:CRDF)

52.97% of Cardiff Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cardiff Oncology Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/14/2021Kennedy Capital Management Inc.268,373$2.49M0.1%+70.4%0.715%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp14,349$0.13M0.0%-9.3%0.038%Search for SEC Filing on Google Icon
5/13/2021Citigroup Inc.21,873$0.20M0.0%-8.6%0.058%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp46,597$0.43M0.0%+4.7%0.124%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC208,455$1.93M0.0%+2.7%0.555%Search for SEC Filing on Google Icon
5/12/2021Frazier Management LLC293,500$2.72M0.2%-48.4%0.782%Search for SEC Filing on Google Icon
5/12/2021JPMorgan Chase & Co.3,735$35K0.0%+86.7%0.010%Search for SEC Filing on Google Icon
5/11/2021Mercer Global Advisors Inc. ADV157,857$1.46M0.0%+16.2%0.420%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.536,758$4.97M0.0%+17.4%1.429%Search for SEC Filing on Google Icon
5/6/2021Blueshift Asset Management LLC14,487$0.13M0.0%N/A0.039%Search for SEC Filing on Google Icon
5/6/2021Prospera Financial Services Inc26,650$0.25M0.0%-42.4%0.071%Search for SEC Filing on Google Icon
5/4/2021Migdal Insurance & Financial Holdings Ltd.33,064$0.31M0.0%+163.6%0.088%Search for SEC Filing on Google Icon
4/28/2021America First Investment Advisors LLC4,000$37K0.0%N/A0.011%Search for SEC Filing on Google Icon
2/19/2021JPMorgan Chase & Co.2,001$36K0.0%N/A0.006%Search for SEC Filing on Google Icon
2/18/2021Truist Financial Corp115,000$2.07M0.0%N/A0.326%Search for SEC Filing on Google Icon
2/16/2021Tri Locum Partners LP157,403$2.83M1.0%N/A0.446%Search for SEC Filing on Google Icon
2/16/2021Pura Vida Investments LLC100,000$1.80M0.1%N/A0.283%Search for SEC Filing on Google Icon
2/16/2021Price T Rowe Associates Inc. MD529,627$9.53M0.0%-4.3%1.499%Search for SEC Filing on Google Icon
2/16/2021Caxton Corp2,114,840$38.05M23.7%+14.6%5.987%Search for SEC Filing on Google Icon
2/16/2021Avidity Partners Management LP1,607,000$28.91M0.9%N/A4.549%Search for SEC Filing on Google Icon
2/16/2021Janus Henderson Group PLC2,137,671$38.43M0.0%+111.1%6.051%Search for SEC Filing on Google Icon
2/16/2021ExodusPoint Capital Management LP40,113$0.72M0.0%N/A0.114%Search for SEC Filing on Google Icon
2/12/2021Opaleye Management Inc.1,662,500$29.91M3.9%-4.0%4.706%Search for SEC Filing on Google Icon
2/12/2021LPL Financial LLC15,964$0.29M0.0%+12.8%0.045%Search for SEC Filing on Google Icon
2/12/2021Credit Suisse AG58,396$1.05M0.0%N/A0.165%Search for SEC Filing on Google Icon
2/12/2021Prospera Financial Services Inc46,284$0.83M0.1%N/A0.131%Search for SEC Filing on Google Icon
2/12/2021Kennedy Capital Management Inc.157,535$2.83M0.1%N/A0.446%Search for SEC Filing on Google Icon
2/12/2021Virtus ETF Advisers LLC14,533$0.26M0.1%N/A0.041%Search for SEC Filing on Google Icon
2/11/2021Northern Trust Corp44,520$0.80M0.0%+79.4%0.126%Search for SEC Filing on Google Icon
2/11/2021Citigroup Inc.23,928$0.43M0.0%+199,300.0%0.068%Search for SEC Filing on Google Icon
2/11/2021Frazier Management LLC568,500$10.23M0.8%+118.7%1.609%Search for SEC Filing on Google Icon
2/9/2021Wells Fargo & Company MN42,120$0.76M0.0%+8,047.0%0.119%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp15,816$0.29M0.0%-74.7%0.045%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.457,201$8.22M0.0%+31.6%1.294%Search for SEC Filing on Google Icon
1/29/2021Emerald Mutual Fund Advisers Trust193,133$3.47M0.1%-42.1%0.547%Search for SEC Filing on Google Icon
1/29/2021Emerald Advisers LLC214,376$3.86M0.1%-40.3%0.607%Search for SEC Filing on Google Icon
1/21/2021Kestra Private Wealth Services LLC33,500$0.59M0.0%+12.9%0.095%Search for SEC Filing on Google Icon
1/20/2021Pacer Advisors Inc.5,362$96K0.0%N/A0.015%Search for SEC Filing on Google Icon
1/8/2021Carroll Financial Associates Inc.3,710$66K0.0%N/A0.011%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC20,604$0.29M0.1%N/A0.058%Search for SEC Filing on Google Icon
12/4/2020Sei Investments Co.44,886$0.64M0.0%N/A0.127%Search for SEC Filing on Google Icon
11/17/2020VR Adviser LLC1,271,985$18.05M3.5%N/A3.601%Search for SEC Filing on Google Icon
11/17/2020Schonfeld Strategic Advisors LLC171,527$2.43M0.0%+187.3%0.486%Search for SEC Filing on Google Icon
11/17/2020Polar Capital LLP472,908$6.71M0.0%N/A1.339%Search for SEC Filing on Google Icon
11/16/2020Polar Capital LLP472,908$6.71M0.1%N/A1.339%Search for SEC Filing on Google Icon
11/16/2020Caxton Corp1,845,164$26.18M24.7%+15.7%5.223%Search for SEC Filing on Google Icon
11/13/2020Morgan Stanley11,620$0.17M0.0%-52.3%0.049%Search for SEC Filing on Google Icon
11/12/2020Sphera Funds Management LTD.40,000$0.57M0.1%N/A0.169%Search for SEC Filing on Google Icon
11/9/2020LPL Financial LLC14,150$0.20M0.0%N/A0.060%Search for SEC Filing on Google Icon
11/9/2020Kestra Private Wealth Services LLC29,662$0.42M0.0%N/A0.125%Search for SEC Filing on Google Icon
11/6/2020Sei Investments Co.44,886$0.64M0.0%N/A0.190%Search for SEC Filing on Google Icon
11/6/2020BlackRock Inc.347,474$4.93M0.0%+6,163.0%1.468%Search for SEC Filing on Google Icon
11/3/2020Corriente Advisors LLC910,000$12.91M6.5%+424.9%3.844%Search for SEC Filing on Google Icon
10/28/2020Emerald Advisers LLC359,335$5.10M0.2%N/A1.518%Search for SEC Filing on Google Icon
10/28/2020Emerald Mutual Fund Advisers Trust333,507$4.73M0.2%N/A1.409%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cardiff Oncology logo
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Read More on Cardiff Oncology

Today's Range

Now: $8.55
$8.40
$9.07

50 Day Range

MA: $9.23
$8.06
$10.48

52 Week Range

Now: $8.55
$1.39
$25.50

Volume

423,469 shs

Average Volume

1,473,085 shs

Market Capitalization

$321.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

Who are the company insiders with the largest holdings of Cardiff Oncology?

Cardiff Oncology's top insider shareholders include:
  1. Gary W Pace (Director)
  2. Mark Erlander (CEO)
  3. John P Brancaccio (Director)
  4. Rodney S Markin (Director)
  5. Vicki Kelemen (COO)

Who are the major institutional investors of Cardiff Oncology?

Cardiff Oncology's top institutional shareholders include:
  1. BlackRock Inc. — 1.43%
  2. Frazier Management LLC — 0.78%
  3. Kennedy Capital Management Inc. — 0.71%
  4. Geode Capital Management LLC — 0.56%
  5. Mercer Global Advisors Inc. ADV — 0.42%
  6. Northern Trust Corp — 0.12%

Which major investors are selling Cardiff Oncology stock?

In the last quarter, CRDF stock was sold by these institutional investors:
  1. Frazier Management LLC
  2. Prospera Financial Services Inc
  3. Citigroup Inc.
  4. Bank of New York Mellon Corp

Which major investors are buying Cardiff Oncology stock?

During the previous quarter, CRDF stock was acquired by institutional investors including:
  1. Kennedy Capital Management Inc.
  2. BlackRock Inc.
  3. Mercer Global Advisors Inc. ADV
  4. Migdal Insurance & Financial Holdings Ltd.
  5. Blueshift Asset Management LLC
  6. Geode Capital Management LLC
  7. America First Investment Advisors LLC
  8. Northern Trust Corp
Within the previous year, these company insiders have bought Cardiff Oncology stock:
  1. Gary W Pace (Director)
  2. Mark Erlander (CEO)
  3. John P Brancaccio (Director)
  4. Rodney S Markin (Director)
  5. Vicki Kelemen (COO)
Gain the Knowledge You Need to Successfully Trade Futures Markets
Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.
Download Your Complimentary Technical Analysis Guide TODAY!
pixel